MoonLake Immunotherapeutics Announced Primary Endpoint HISCR75 Met With 29 Percentage Points Delta Vs Placebo (P=0.0002) At Week 12 In Hidradenitis Suppurativa
Portfolio Pulse from Charles Gross
MoonLake Immunotherapeutics (NASDAQ:MLTX) announced positive top-line results from its Phase 2 MIRA trial evaluating the efficacy and safety of sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS). The trial met its primary endpoint, HISCR75, with a 29 percentage points delta vs placebo at week 12 (P=0.0002).
June 25, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MoonLake Immunotherapeutics' positive Phase 2 MIRA trial results for sonelokimab in hidradenitis suppurativa patients may boost investor confidence and stock price.
The positive results from the Phase 2 MIRA trial indicate that MoonLake's sonelokimab has potential in treating moderate-to-severe hidradenitis suppurativa. This may lead to increased investor confidence in the company's ability to develop effective therapies, potentially driving the stock price up.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100